Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Cited by (1,000)

Items 601–700 of 1,000

1. Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population
   Yasar Sattar, Pradeeksha Mukuntharaj, Mohamed Zghouzi, Abdul‐Rahman M. Suleiman, Hassan Bin Attique, Waqas Ullah, Muhammad Khawar Sana, Nathan Zaher, Maham Mehmood, Rajkumar Prakashbhai Doshi et al. · 2021 · High Blood Pressure & Cardiovascular Prevention
2. Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model
   Philipp Reus, Ann‐Kathrin Schneider, Thomas Ulshöfer, Marina Henke, Denisa Bojková, Jindrich Jr. Cinatl, Sandra Ciesek, Gerd Geißlinger, Volker Laux, Mira Grättinger et al. · 2021 · Life
3. Ultra Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (UPLC-Q-TOF-MS)-based metabolomic analysis of mycelial biomass of three Ganoderma isolates from the Lower Volta River Basin of Ghana
   Gideon Adotey, Raphael Nammahime Alolga, Abraham Quarcoo, Mohammed Ahmed Gedel, Abraham Kwabena Anang, John C. Holliday · 2021 · Journal of Pharmaceutical and Biomedical Analysis
4. COVID-19 signalome: Potential therapeutic interventions
   Kenneth H. Lundstrom, Altijana Hromić‐Jahjefendić, Esma Bilajac, Alaa A. A. Aljabali, Katarina Baralić, Nagwa A. Sabri, Eslam Mansour Shehata, Mohamed Raslan, Sara Ahmed Raslan, Ana Cláudia Barbosa Honório Ferreira et al. · 2022 · Cellular Signalling
5. A Critical Review on the Long-Term COVID-19 Impacts on Patients With Diabetes
   Sumel Ashique, Neeraj Mishra, Ashish Garg, Sweta Garg, Arshad Farid, Shweta Rai, Gaurav Gupta, Kamal Dua, Keshav Raj Paudel, Farzad Taghizadeh‐Hesary · 2024 · The American Journal of Medicine
6. Renin–Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study
   Christian Fynbo Christiansen, Uffe Heide‐Jørgensen, Thomas Bøjer Rasmussen, Jacob Bodilsen, Ole Schmeltz Søgaard, Michael Mæng, Simon Tilma Vistisen, Morten Schmidt, Anton Pottegård, Lars Christian Lund et al. · 2020 · Journal of the American Heart Association
7. Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection
   James A. Russell, John C. Marshall, Arthur S. Slutsky, Srinivas Murthy, Dave Sweet, Terry Lee, Joel Singer, David M. Patrick, Bin Du, Zhiyong Peng et al. · 2020 · BMJ Open
8. Low plasma angiotensin-converting enzyme 2 level in diabetics increases the risk of severe COVID-19 infection
   Yanliang Zhang, Yangyang Sun, Kang Liu, Raphael Nammahime Alolga, Xueqiang Xu, Ganzhu Feng, Pingxi Xiao · 2021 · Aging
9. COVID-19: Critical Role of Angiotensin 1-7 in ACE2 Modulation
   Ching Siang Tan, Siang Fei Yeoh, Chiau Ming Long · 2020 · Annals of the Academy of Medicine Singapore
10. Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
    Chao Zhang, Jun Zhong, Weixiang Chen, Xu-Yang Zhang, Yuhong Li, Tengyuan Zhou, Yongjie Zou, Chuan Lan, Lan Li, Zhaopan Lai et al. · 2021 · Neuropsychiatric Disease and Treatment
11. Genetic liability between COVID-19 and heart failure: evidence from a bidirectional Mendelian randomization study
    Huachen Wang, Zheng Guo, Yulu Zheng, Bing Chen · 2022 · BMC Cardiovascular Disorders
12. Role of the RAAS in mediating the pathophysiology of COVID-19
    Jakub Jasiczek, Adrian Doroszko, Tymoteusz Trocha, Małgorzata Trocha · 2024 · Pharmacological Reports
13. The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review
    Dan Luo, Mengzhe Bai, Wei Yan Zhang, Junnan Wang · 2024 · Frontiers in Cardiovascular Medicine
14. COVID-19 pandemic and cardiovascular disease: where do we stand?
    Dimitrios Chatzis, Kalliopi Magounaki, Ioannis N. Pantazopoulos, Elizabeth O. Johnson, Konstantinos P Tsioufis · 2020 · Minerva Cardioangiologica
15. Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
    Oksana M. Drapkina, L. E. Vasilyeva · 2020 · CARDIOVASCULAR THERAPY AND PREVENTION
16. Increased plasma ACE2 concentration does not mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19
    Xueting Li, Ying Liu, Juanjuan Song, Jiuchang Zhong · 2020 · Acta Pharmaceutica Sinica B
17. Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis
    Mathieu Kernéis, Arnaud Ferrante, Paul Guedeney, Éric Vicaut, Gilles Montalescot · 2020 · Archives of cardiovascular diseases
18. Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
    Rodolfo Pedro Rothlin, Facundo Germán Pelorosso, Mariano Duarte, Liliana Nicolosi, Ignacio Fernandez Criado, María Victoria Salgado, Héctor Miguel Vetulli · 2023 · Pharmacology Research & Perspectives
19. Study of kaempferol in the treatment of COVID-19 combined with Chikungunya co-infection by network pharmacology and molecular docking technology
    Md. Arju Hossain, Md Sohel, Tayeba Sultana, Md Imran Hasan, Md. Sharif Khan, K. M. Kaderi Kibria, S.M. Hasan Mahmud, Md Habibur Rahman · 2023 · Informatics in Medicine Unlocked
20. Renin-angiotensin system inhibitors in COVID-19
    George Thomas · 2020 · Cleveland Clinic Journal of Medicine
21. Angiotensin II administration to COVID-19 patients is not advisable
    Robert Charles Speth · 2020 · Critical Care
22. Repurposing current therapeutic regimens against SARS-CoV-2 (Review)
    Sofia Marina Konstantinidou, Ioannis P. Papanastasiou · 2020 · Experimental and Therapeutic Medicine
23. Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19
    Mark Laws, Yasmin M. Surani, Md. Mahbub Hasan, Yiyuan Chen, Peiqin Jin, Taha Al‐Adhami, Madiha Chowdhury, Aqeel Imran, Ioannis Psaltis, Shirin Jamshidi et al. · 2020 · Current Medicinal Chemistry
24. COVID-19 and renin-angiotensin system modulators: what do we know so far?
    Angel De La Cruz, Shoaib Ashraf, Timothy J. Vittorio, Jonathan N. Bella · 2020 · Expert Review of Cardiovascular Therapy
25. COVID-19 and Cardiovascular Health Among Patients with Cancer
    Nicolas L. Palaskas, Efstratios Koutroumpakis, Anita M Deswal · 2020 · Current Cardiology Reports
26. SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes
    Vikas Kumar Bhari, Durgesh Kumar, Surendra Kumar, Rajeev Mishra · 2020 · Biochemistry and Biophysics Reports
27. Cardiovascular implications and complications of the coronavirus disease-2019 pandemic: a world upside down
    Antonis S. Manolis, Theodora A. Manolis, Antonis S. Manolis, Helen Melita · 2020 · Current Opinion in Cardiology
28. No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study
    Roos S. G. Sablerolles, Freija E. F. Hogenhuis, Melvin Lafeber, Bob P. A. van de Loo, Sander Diederik Borgsteede, Eric H. Boersma, Jorie Versmissen, P.H.M. van der Kuy · 2021 · British Journal of Clinical Pharmacology
29. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
    Isabela Macedo Lopes Vasques‐Monteiro, Vanessa Souza‐Mello · 2021 · World Journal of Gastroenterology
30. Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition)
    Vladimir B. Grinevich, Yu. A. Kravchuk, V. I. Ped, Evgenii I. Sas, Саликова Светлана Петровна, Губонина Ирина Владимировна, Tkachenko Ei, Stanislav I. Sitkin, Leonid Borisovich Lazebnik, Е. В. Голованова et al. · 2021 · Экспериментальная и клиническая гастроэнтерология
31. Genetic‐based adaptive momentum estimation for predicting mortality risk factors for COVID ‐19 patients using deep learning
    Sally M. Elghamrawy, Aboul Ella Hassanien, Athanasios V. Vasilakos · 2021 · International Journal of Imaging Systems and Technology
32. The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID‐19 and Hypertension: A Mini‐Review
    Farnoosh Nozari, Nasrin Hamidizadeh · 2022 · International Journal of Hypertension
33. The clinical and bioinformatics analysis for the role of antihypertension drugs on mortality among patients with hypertension hospitalized with COVID‐19
    Liyang Zhao, Yusi Li, Wenjuan Yi, Kuo Yan, Chao Yang, Radhakrishnan Sridhar, Rui Li, Ruirong Tan, Gang Fan, Mengyuan Dai et al. · 2022 · Journal of Medical Virology
34. Drugs acting on the renin–angiotensin–aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies
    Ruchika Sharma, Anoop Kumar, Jaseela Majeed, Ajit Kumar Thakur, Geeta Aggarwal · 2022 · The Egyptian Heart Journal
35. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19
    Augusto Filippo Di Castelnuovo, Raffaele De Caterina, Giovanni de Gaetano, Licia Iacoviello · 2020 · Hypertension
36. ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study
    Luc Dauchet, M. Lambert, Victoria Gauthier, Julien Poissy, Karine Faure, Alain Facon, Cécile Yelnik, Sophie Panaget, Thierry Plagnieux, Florent Verfaillie et al. · 2020 · medRxiv
37. Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
    Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Andrea Filipponi, Francesco Spannella · 2020 · Internal and Emergency Medicine
38. Statin Treatment of COVID-19
    David S. Fedson · 2020 · The American Journal of Cardiology
39. Emerging mechanisms for the new Coronavirus-related myocardial injury and ischemia, a review of the literature
    Mohammad Mostafa Ansari Ramandi · 2020 · The Anatolian Journal of Cardiology
40. General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection
    Min Young Kim, Daniel C. Brennan, Pali D. Shah · 2020 · Current Transplantation Reports
41. Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19
    Hongwei Peng, Zhang-Ren Chen, Yunyun Wang, Simei Ren, Tiantian Xu, Xin Lai, Jinhua Wen, Meng-jun Zhao, Chuanfei Zeng, Lijuan Du et al. · 2020 · Frontiers in Pharmacology
42. Metabolic Syndrome “Interacts” With COVID-19
    Zeling Guo, Shanping Jiang, Zilun Li, Sifan Chen · 2020 · BIO Integration
43. COVID-19 Outcomes Amongst Patients With Pre-existing Cardiovascular Disease and Hypertension
    Raja Chandra Chakinala, Chail Shah, Jigisha Rakholiya, Mehwish Martin, Nirmaljot Kaur, Harmandeep Singh, Toochukwu Lilian Okafor, Chika Nwodika, Payu Raval, Salma Yousuf et al. · 2021 · Cureus
44. Medication use during COVID-19
    T.S. Brandon Ng, Kori Leblanc, Darwin F. Yeung, Teresa S.M. Tsang · 2021 · Canadian Family Physician
45. RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives
    Mykola D. Khalangot, Nadiia Sheichenko, Vitaliy G. Gurianov, T.F. Zakharchenko, Victor I Kravchenko, Mykola D. Tronko · 2023 · Frontiers in Endocrinology
46. Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era
    Qian Cao, Xin Du, Xiao‐Yan Jiang, Yuan Tian, Chen-hao Gao, Ziyu Liu, Ting Xu, Xingxing Tao, Ming Lei, Xiaoqiang Wang et al. · 2023 · Acta Pharmacologica Sinica
47. Myocardial injury and related mortality in hospitalized patients with COVID-19 during the Omicron pandemic: new perspectives and insights
    Wu He, Ke Xu, Li Ni, Junfang Wu, Yuxuan Zhang, Kun Miao, Luyun Wang, Dao Wen Wang · 2023 · Virologica Sinica
48. Prognostic significance of hypertension history and blood pressure on admission in Japanese patients with coronavirus disease 2019: integrative analysis from the Japan COVID-19 Task Force
    Kaori Sakurai, Shotaro Chubachi, Takanori Asakura, Ho Namkoong, Hiromu Tanaka, Shuhei Azekawa, Takashi Shimada, Shiro Otake, Kensuke Nakagawara, Takahiro Fukushima et al. · 2023 · Hypertension Research
49. Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues
    Silvia Fogacci, Federica Fogacci, Elda Favari, Peter Paul Toth, Claudio Borghi, Arrigo F.G. Cicero · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
50. Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study
    Olena Bolotova, Jeanwoo Yoo, Imran Chaudhri, Luis A. Marcos, Haseena Sahib, Farrukh M. Koraishy, Hal A. Skopicki, Sahar Ahmad, Sandeep K. Mallipattu · 2020 · PLoS ONE
51. What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19
    Vicki Osborne, Saad Shakir · 2021 · Frontiers in Pharmacology
52. Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study
    Molly M. Jeffery, Nathan W. Cummins, Timothy M. Dempsey, ANDREW HAR LIMPER, Nilay D. Shah, Fernanda Bellolio · 2021 · BMJ Open
53. The therapeutic effect and safety of the drugs for COVID-19
    Rong Qiu, Jingwei Li, Yuxuan Xiao, Ziyi Gao, Yihang Weng, Qiran Zhang, Chengdi Wang, Hanlin Gong, Weimin Li · 2021 · Medicine
54. Association Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in Hospitalized Patients
    Bin Wu, Zhou Jianghua, W Z Wang, Huilin Yang, Xia Meng, 张丙宏, She Zhi‐Gang, LI Hong-liang · 2021 · Chinese Medical Sciences Journal
55. COVID-19 and Cardiovascular Diseases
    Babak Geraiely, Niloufar Samiei, Parham Sadeghipour, Azita H. Talasaz, Seyedeh Hamideh Mortazavi, Roya Sattarzadeh Badkoubeh · 2021 · Advances in experimental medicine and biology
56. Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
    Si‐Hyuck Kang, Dong-Hoon Lee, Kyungdo Han, Jin‐Hyung Jung, Sang Hyun Park, Andrew M. Dai, Henry G. Wei, Chang‐Hwan Yoon, Tae‐Jin Youn, In‐Ho Chae et al. · 2021 · Clinical Hypertension
57. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19
    Emilia Roy‐Vallejo, Aquilino Sánchez Purificación, José David Torres-Peña, Beatriz Sánchez Moreno, Francisco Arnalich, María José García Blanco, José López‐Miranda, Juan Luis Romero‐Cabrera, Carmen Rosario Herrero Gil, José Bascuñana et al. · 2021 · Journal of Clinical Medicine
58. Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium
    José Luis Peñalvo, Els Genbrugge, Elly Mertens, Diana Sagastume, Marianne A. B. van der Sande, Marc‐Alain Widdowson, Dominique Van Beckhoven · 2021 · BMJ Open
59. Association of blood glucose level and prognosis of inpatients with coexistent diabetes and COVID-19
    Weiwei Duan, Liangyu Li, Xuesong Li, Mengyan Zhu, Lingxiang Wu, Wei Wu, Kening Li, Yuan Liang, Rong Ding, Wenhua You et al. · 2021 · Endocrine
60. Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2
    John Matsoukas, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Konstantinos Kelaidonis, Irene Ligielli, Kalliopi Moschovou, Nikitas Georgiou, Panagiotis Plotas, Christos T. Chasapis et al. · 2022 · Biomedicines
61. An Update of Carbazole Treatment Strategies for COVID-19 Infection
    Maria Grazia Bonomo, Anna Caruso, Hussein El‐Kashef, Giovanni Salzano, Maria Stefania Sinicropi, Carmela Saturnino · 2023 · Applied Sciences
62. Challenges in Women with Diabetes During the COVID-19 Pandemic
    Gagan Priya, Sarita Bajaj, Emmy Grewal, Indira Maisnam, Sruti Chandrasekharan, Chitra Selvan · 2020 · touchREVIEWS in Endocrinology
63. Considerations When Managing Heart Failure during the COVID-19 Pandemic-Consensus from the Taiwan Society of Cardiology.
    Kun-Chang Lin, Chun-Chieh Wang, Wei-Chun Huang, Juey-Jen Hwang · 2021 · PubMed Central
64. Interactions amongst inflammation, renin-angiotensin-aldosterone and kallikrein-kinin systems: suggestive approaches for COVID-19 therapy
    Lilian Caroline Gonçalves de Oliveira, Nayara Azinheira Nobrega Cruz, Bruna Ricelli, Helio Tedesco Silva Junior, José Osmar Medina-Pestana, Dulce Elena Casarini · 2021 · The Journal of venomous animals and toxins including tropical diseases
65. ACEing COVID-19
    Venkatesh Locharla Murthy, Milka Koupenova, Ravi V. Shah · 2020 · Circulation Research
66. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the “Ariadne's thread” for the “labyrinth” of COVID-19
    Costas P. Tsioufis, Kyriakos S. Dimitriadis, Dimitrios M. Tousoulis · 2020 · Hellenic Journal of Cardiology
67. SARS, MERS, COVID-19: Identification of Patients at a Higher Risk: A Narrative Review
    Hussein A Noureldine, Georges Chedid, Jad Gerges Harb, Wared Nour‐Eldine, Mariam Nour Eldine, Mohammad Hassan A. Noureldine, Dany Abou Abdallah, Nancy Falco Chedid · 2021 · International Journal of Clinical Research
68. Resilience and response of the congenital cardiac network in Italy during the COVID-19 pandemic
    Roberto Formigari, Simona Anna Marcora, Giovanni Battista Luciani, Silvia Favilli, Gabriele Egidy Assenza, Gabriele Rinelli, Giovanni Meliota, Biagio Castaldi, Giuseppe Limongelli, Serena Francesca Flocco et al. · 2020 · Journal of Cardiovascular Medicine
69. Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19
    Dong Xiang, Xiuhua Ren, Qian Chen, Hengyi Yu, Xiping Li, Dong Liu · 2020 · Clinical and Experimental Hypertension
70. ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO)
    Irma Bisceglia, Domenico Gabrielli, Maria Laura Canale, Giuseppina Gallucci, Iris Parrini, Fabio Maria Turazza, Giulia Russo, Nicola Maurea, Vincenzo Quagliariello, Chiara Lestuzzi et al. · 2021 · European Heart Journal Supplements
71. Hypertensive urgencies during the first wave of COVID-19 pandemic in a tertiary hospital setting: A “U” shaped alarming curve.
    Ioannis Leontsinis, Niki Katsiki, Vasilios Papademetriou, Christina A. Chrysohoou, Maria G. Kariori, Ioannis Dalakouras, P. Tolis, Christos Fragoulis, Theodoros Kalos, Tatakis Fotios-Panagiotis et al. · 2021 · Archives of Medical Science
72. The Impact of Obesity on SARS-CoV-2 Pandemic Mortality Risk
    Zhaoping Li, Vijaya Surampudi, David Heber · 2021 · Nutrients
73. Renin-Angiotensin-Aldosterone System
    Robert Charles Speth · 2021 · Elsevier eBooks
74. An Updated Review on Complicated Mechanisms of COVID-19 Pathogenesis and Therapy: Direct Viral Damage, Renin-angiotensin System Dysregulation, Immune System Derangements, and Endothelial Dysfunction
    Shahab Falahi, Maryam Maleki, Azra Kenarkoohi · 2022 · Infectious Disorders - Drug Targets
75. The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment
    Langjiao Liu, Haijiao Jing, Xiaoming Wu, Mengqi Xiang, Valerie Anne Novakovic, Shuye Wang, Jialan Shi · 2022 · Frontiers in Cardiovascular Medicine
76. Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection
    Angelina Zhyvotovska, Denis Yusupov, Robert Foronjy, Mohammed Nakeshbandi, Samy I. McFarlane, Moro O. Salifu · 2020 · International Journal of Clinical Research & Trials
77. Management of COVID-19 in a durable left ventricular assist device recipient: A continuity of care perspective
    Sai Krishna C. Korada, James Arthur Mann, Ayesha K. Hasan, Ragavendra R. Baliga, Nahush Ashok Mokadam, Raymond L. Benza, Ajay Vallakati · 2020 · Heart & Lung
78. COVID-19 pandemic: challenges ahead
    Horacio Márquez-González, Marı́a Guadalupe Miranda-Novales, Fortino Solórzano‐Santos, Miguel Klünder‐Klünder, Juan Garduño‐Espinosa, Jorge Fernando Méndez-Galván · 2020 · Boletín Médico del Hospital Infantil de México
79. Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
    Andrea Laurentius, Brian Mendel, Radityo Prakoso · 2021 · The Egyptian Heart Journal
80. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts
    Katrina Armstrong, Alexander E. Soltoff, Meghan L. Rieu‐Werden, Joshua P. Metlay, Jennifer S. Haas · 2021 · PLoS ONE
81. Cardiac Involvement in COVID-19
    Akhmetzhan Sugraliyev · 2021 · Kardiologiia
82. Effects of the Na + /H + Ion Exchanger on Susceptibility to COVID-19 and the Course of the Disease
    Medine Cumhur Cüre, Erkan Cüre · 2021 · Journal of the Renin-Angiotensin-Aldosterone System
83. Mechanism and transmission routes of COVID-19
    Lokeshwaran Kirubananthan, Ramanaiah Illuri, Ramesh Rajendran, Prasanna Raja Chandrasekaran · 2021 · Elsevier eBooks
84. Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality
    Malindu E. Fernando, Aaron D. Drovandi, Jonathan Golledge · 2021 · Systematic Reviews
85. COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases
    Yuanyuan Zhang, Mingjie Wang, Xian Zhang, Tianxiao Liu, Peter Libby, Guo-Ping Shi · 2021 · Cardiology Discovery
86. Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study
    Kei Sato, Nicole Marie White, Jonathon Paul Fanning, Nchafatso G. Obonyo, Michael H. Yamashita, Vinesh Appadurai, Anna L. Ciullo, Meryta May, Elliott T Worku, Leticia Helms et al. · 2022 · BMC Cardiovascular Disorders
87. ACEi/ ARB and Deaths of COVID-19 Patients
    Anoop Kumar, Gulam Navi Azad · 2022 · Current Hypertension Reviews
88. Consequences of COVID-19 on the cardiovascular and renal systems
    Yuan Zhu, Xiaoyi Zhang, Zhiyong Peng · 2022 · Sleep Medicine
89. Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers
    Yu. V. Mareev, Mareev VIu · 2020 · Kardiologiia
90. Evidence That Renin-Angiotensin System Inhibitors Should Not Be Discontinued Due to the COVID-19 Pandemic
    Robert M. Carey, Ji‐Guang Wang · 2020 · Hypertension
91. COVID-19 and cardiovascular comorbidities: An update
    Rogerio P. Teixeira, Mário Santos, Victor Machado Gil · 2020 · Revista Portuguesa de Cardiologia
92. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019
    Sang Heon Suh, Seong Kwon, Soo Wan Kim, Eun Hui Bae · 2020 · The Korean Journal of Internal Medicine
93. Whey-Derived Peptides at the Heart of the COVID-19 Pandemic
    Yara Chamata, Kim G. Jackson, Kimberly A. Watson, Paula Jauregi · 2021 · International Journal of Molecular Sciences
94. COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics)
    Michael A. Chary, Alexander F. Barbuto, Sudeh Izadmehr, Marc Tarsillo, Eduardo Fleischer, Michele M. Burns · 2022 · Journal of Medical Toxicology
95. Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19
    Seiji Hamada, Tomoharu Suzuki, Yasuharu Tokuda, Kiyosu Taniguchi, Kenji Shibuya · 2023 · Scientific Reports
96. Beneficial Effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: A Retrospective Study from 2019 to 2020 in China
    Ke Xu, Wu He, Bo Yu, Kaineng Zhong, Da Zhou, Dao Wen Wang · 2023 · Cardiovascular Drugs and Therapy
97. The Risk Factors of COVID-19 Infection and Mortality among Older Adults in South Korea
    Sungmin Lee, Jungha Park, Jae-Ryun Lee, Jin Yong Lee, Byung Sung Kim, Chang Won Won, Hyejin Lee, Sun Young Kim · 2023 · Annals of Geriatric Medicine and Research
98. In silico prediction of preventive activities of bioactive hazelnut peptides against COVID ‐19 and Monkeypox 2022
    Zeynep Saliha Güneş, Bilal Çakır, İbrahim Gülseren · 2024 · Peptide Science
99. Can adverse cardiac events of the COVID-19 vaccine exacerbate preexisting diseases?
    Mohammed Shawkat Razzaque · 2024 · Expert Review of Anti-infective Therapy
100. Density functional theory and enzyme studies support interactions between angiotensin receptor blockers and angiotensin converting enzyme-2: Relevance to coronavirus 2019
     Vasso Apostolopoulos, Nikitas Georgiou, Demeter Tzeli, Thomas Mavromoustakos, Graham J. Moore, Konstantinos Kelaidonis, Minos–Timotheos Matsoukas, Sotirios Tsiodras, Jordan Swiderski, Laura Kate Gadanec et al. · 2024 · Bioorganic Chemistry